Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 2/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | ALDH2 | P05091 | 2/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1530745 | 0.91 | CRBN (0.66) | CRBNCYP3A4BRD4DDB1 | |
| SCHEMBL1530701 | 0.89 | CRBN (0.64) | CRBNCYP3A4BRD4 | |
| SCHEMBL1531039 | 0.89 | CRBN (0.63) | CRBNCYP3A4BRD4 | |
| SCHEMBL1530321 | 0.89 | CRBN (0.63) | CRBNCYP3A4BRD4 | |
| SCHEMBL15419007 | 0.88 | CRBN (0.62) | CRBNCYP3A4BRD4 | |
| SCHEMBL1530679 | 0.87 | CRBN (0.59) | CRBNCYP3A4BRD4 | |
| SCHEMBL1530851 | 0.87 | CRBN (0.54) | CRBN | |
| SCHEMBL1530897 | 0.86 | CRBN (0.60) | CRBNCYP3A4 | |
| SCHEMBL1530227 | 0.85 | CRBN (0.59) | CRBNCYP3A4 | |
| SCHEMBL15418900 | 0.85 | CRBN (0.49) | CRBNCYP3A4ALDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9802903-B2 | Process for preparing antiviral compound | ABBVIE INC. (US) | 2017-10-31 | — | — | US | claimed |
| US-20160060228-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUND | ABBOTT LABORATORIES | 2016-03-03 | — | — | US | claimed |
| US-9216952-B2 | Process for preparing antiviral compound | ABBVIE INC. (US) | 2015-12-22 | — | — | US | claimed |
| EP-2411372-B1 | PROCESS FOR PREPARING AN ANTIVIRAL COMPOUND | ABBVIE BAHAMAS LTD (BS) | 2014-07-23 | — | — | EP | claimed |
| EP-2222646-B1 | URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C | ABBVIE BAHAMAS LTD (BS) | 2014-01-22 | — | — | EP | claimed |
| EP-2411372-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUND | Abbott Laboratories (US) | 2012-02-01 | — | — | EP | claimed |
| US-20110237793-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUND | ABBOTT LABORATORIES (US) | 2011-09-29 | — | — | US | claimed |
| WO-2010111348-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUND | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | WO | claimed |
| US-9802903-B2 | Process for preparing antiviral compound | ABBVIE INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9802903-B2 | Process for preparing antiviral compound | ABBVIE INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9802903-B2 | Process for preparing antiviral compound | ABBVIE INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-20160060228-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUND | ABBOTT LABORATORIES | 2016-03-03 | — | — | US | disclosed |
| US-20160060228-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUND | ABBOTT LABORATORIES | 2016-03-03 | — | — | US | disclosed |
| US-20160060228-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUND | ABBOTT LABORATORIES | 2016-03-03 | — | — | US | disclosed |
| US-8415351-B2 | Anti-infective agents and uses thereof | ABBOTT LABORATORIES (US) | 2013-04-09 | — | — | US | disclosed |
| EP-2411372-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUND | Abbott Laboratories (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20110237793-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUND | ABBOTT LABORATORIES (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237793-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUND | ABBOTT LABORATORIES (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237793-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUND | ABBOTT LABORATORIES (US) | 2011-09-29 | — | — | US | disclosed |
| WO-2010111348-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUND | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237793-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUND | ZC3HAV1, HAVCR2, MAVS | CRBN 2332/4885CYP3A4 96/4885ALDH2 3150/4885 |
| US-20160060228-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUND | ZC3HAV1, HAVCR2, MAVS | CRBN 2332/4885CYP3A4 96/4885ALDH2 3150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.